bms-1

BMS-1 (PD-1 PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1) programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1 PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1 PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

BMS-1001 is a potent inhibitor of PD-1 PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).

BMS-1001 hydrochloride is an orally active inhibitor of human PD-1 PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is capable of alleviating the PD-1 PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.

Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM). BMS-1166 hydrochloride is an inhibitor of PD-1 PD-L1 interaction (IC50: 1.4 nM). BMS-1166 rivalries the inhibitory effect of PD-1 PD-L1 immune checkpoint on T cell activation.

BMS-196085 is an effective and selective human β( 3) All agonists of adrenergic receptors, in β( 1) Partial agonist activity was 45%.

BMS-1166-N-piperidine-COOH is a chemical compound that functions as the BMS-1166-based moiety. It binds to the E3 ligase ligand through a linker, leading to the formation of PROTAC PD-1/PD-L1 degrader-1, which facilitates the degradation of PD-1/PD-L1. BMS-1166 demonstrates potent inhibition of PD-1/PD-L1 interaction, with an IC 50 of 1.4 nM. By antagonizing the inhibitory effect of the PD-1/PD-L1 immune checkpoint on T cell activation, BMS-1166 promotes T cell activation.

BMS-1166-N-piperidine-CO-N-piperazine is a chemical compound containing a PD-1 PD-L1 immune checkpoint ligand and a PROTAC linker. It is used in synthesizing [PROTAC PD-1 PD-L1 degrader-1], which effectively inhibits the PD-1 PD-L1 interaction with an IC50 value of 39.2 nM.

BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.

BMS-1166 is a potent inhibitor of the PD-1 PD-L1 interaction.

BMS-191011 (BMS-A) is an activator of large-conductance calcium-activated potassium (BKCa) channels ,effective in stroke models

BMS-1233 is an orally effective programmed death ligand 1 (PD-L1) inhibitor with an IC50 of 14.5 nM. This compound promotes the death of HepG2 cells in a co-culture model with Jurkat T cells and exhibits antitumor activity against melanoma in mouse models.

BMS-191095 is mitochondrial ATP-sensitive potassium (mitoKATP) channel activator.

BMS-193885 is a selective, brain-penetrant, and competitive antagonist of the neuropeptide Y1 receptor with a Ki of 3.3 nM, and an IC50 of 5.9 nM for hY1.

BMS-191095 hydrochloride is a mitochondrial KATP channel opener. It offers cardioprotective benefits without causing vasodilation or impacting electrophysiology. Its protective mechanisms include prolonging myocardial contraction during ischemia, enhancing contractile function post-reperfusion, and reducing lactate dehydrogenase (LDH) release.

BMS-185354 is a selective RARγ activator with an EC50 value of 28 nM, offering potential for cancer research.

BMS-189664 is an inhibitor of thrombin.

BMS-189664 HCl is a selective and orally active thrombin active site inhibitor.

BMS-199945 is an Influenza H1N1 Virus inhibitor.

BMS-180492 is a bio-active chemical.

BMS-185411 is a bio-active chemical.

BMS-187308 is an endothelin-A (ETA) selective antagonist.

BMS-188494 is a squalene synthase inhibitor used as an anti-cholesterol drug.